A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Phase 3 Active not recruiting 487 enrolled Eli Lilly and Company

RandomizedParallel-groupDouble-blindTreatment

Summary

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.

Timeline

Start: 2025-04-30
Primary completion: 2027-09
Completion: 2027-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Orforglipron	Small molecule	—	Oral

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Summary

Timeline

Drugs

Indications